Stapokibart  (Synonyms: 司普奇拜单抗; CM310)

Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα (K_D values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively). Stapokibart effectively blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis)^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

Stapokibart 与人、食蟹猴和大鼠的 IL-4Rα 结合，K_D 值分别为 0.25 nM、1.50 nM 和 2.75 nM^[2]。
Stapokibart 阻断 IL-4 与 IL-4Rα 的相互作用，IC₅₀ 为 0.40 nM^[2]。
Stapokibart 抑制 IL-4 诱导的 STAT6 活化，IC₅₀ 为 0.039 nM，并抑制 IL-13 诱导的 STAT6 活化，IC₅₀ 为 0.041 nM^[2]。
Stapokibart 抑制 IL-4 诱导的 TF-1 细胞增殖，IC₅₀其 IC₅₀ 为 1.75 nM，IL-13 诱导的 TF-1 细胞增殖，IC₅₀ 为 0.13 nM^[2]。
Stapokibart 抑制 IL-4 诱导的 Ramos 细胞 CD23 上调，IC₅₀ 为 0.53 nM^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Stapokibart (25-100 mg/kg；皮下注射) 通过抑制气道炎症和降低 IL-4/IL-13 诱发的气道炎症大鼠的炎症细胞因子水平发挥保护作用^[2]。
Stapokibart (25-100 mg/kg；皮下注射) 可改善大鼠卵清蛋白诱发的鼻炎和 AD 样皮炎^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

3566  [NCBI]

P24394

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.3 kDa

2734715-10-5

液体

Colorless to light yellow

司普奇拜单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• [1]. Yuan Zhang, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. EClinicalMedicine. 2023 Jul 5:61:102076.  [Content Brief]

  [2]. Liu W, et al. Stapokibart (CM310) targets IL-4Rα for the treatment of type 2 inflammation. iScience. 2024 Aug 13;27(9):110721.  [Content Brief]